John C. Lechleiter
He received a Bachelor of Science in Chemistry from Xavier University. He went on to receive a Master's degree and a PhD in Organic Chemistry from Harvard University in 1980 on a National Science Foundation Fellowship.
He joined Eli Lilly and company in 1979 as senior organic chemist. From 1984 to 1986, he served as director of pharmaceutical product development at the Lilly Research Centre Limited in Windlesham, England. In 1986, he returned to the US as manager of research and development projects for Europe. He became Director of development projects management in 1988, Executive Director of pharmaceutical product development in 1991, Vice President of pharmaceutical product development in 1993, Vice President of regulatory affairs in 1994, Vice President for development and regulatory affairs in 1996, and Senior Vice President of pharmaceutical products in 1998. In 2001, he was appointed Executive Vice President for pharmaceutical products and corporate development. In a 2003 e-mail, he discussed the use of the anti-schizophrenia or bipolar disorder drug Zyprexa for "disruptive kids", even if it was not approved by federal regulators because it led to diabetes. In 2004, he became Executive Vice President for pharmaceutical operations. In 2005, he became President and CEO, and he joined the Board of Directors. In 2012, he earned US$15.57 million.
He sat on the Board of Directors of Nike, Inc., the Central Indiana Corporate Partnership and the Great Lakes Chemical Corporation. He is a member of the American Chemical Society, the Business Roundtable and The Business Council. He is Chairman of the Pharmaceutical Research and Manufacturers of America and President of the International Federation of Pharmaceutical Manufacturers & Associations.
He sits on the Board of Trustees of his alma mater, Xavier University, the United Way Worldwide and the Life Sciences Foundation. He has received Honorary Doctorates from Marian University, the University of Indianapolis and the National University of Ireland.
- Bloomberg BusinessWeek
- The Wall Street Journal
- Eli Lilly and Company Board of Directors
- Forbes 2012
- Pharmaceutical Research and Manufacturers of America
- John C. Lechleiter Joins Nike's Board of Directors, Press Release, June 18, 2009
- A Conversation with John Lechleiter, Harvard Graduate School of Arts and Sciences, April 10, 2012
- Alex Berenson, Eli Lilly E-Mail Discussed Unapproved Use of Drug, The New York Times, March 15, 2008